Cell Preparation Matched to the Downstream Assay
Preanalytical handling can affect whether a valuable blood sample is usable for vaccine-response research. Alfa Cytology offers PBMC isolation and immune cell preparation services to help research teams define a processing route, recover the required cell population, and document the preparation before a downstream assay begins.
The service focuses on processing and cell preparation, rather than a generic immune-function testing package. We review collection and transport constraints first, then define the isolation method and relevant QC. Acceptance of standalone processing projects, external sample shipment, cryopreservation, and cell return is confirmed during scoping; none is assumed from the service title.
Preparation and QC Modules
PBMC Isolation
Consider an appropriate density-gradient or other agreed isolation workflow for an accepted blood-derived sample. Record the processing route and recovered cell quantity rather than promising a fixed yield from every specimen.
Selected Immune-Cell Enrichment
Discuss preparation of a required subset, such as T cells or monocytes, where the available method and starting material support it. The selection approach is matched to the intended functional assay.
Count, Viability, and Purity Assessment
Select the relevant cell count, viability method, and identity or purity panel. Report the basis for the measurement so total recovered cells are not confused with the requested target-cell yield.
Downstream Assay Handover
Coordinate the preparation record, timing, and cell allocation with an agreed functional assay. Freezing, thawing, storage, or external cell transfer are included only when specifically confirmed in the project scope.
Confirm Sample Acceptance Before Collection
| Information | What to provide | Why it affects feasibility |
|---|---|---|
| Sample source and type | Whole blood, buffy coat, or another proposed material; healthy-donor or research-patient source. | Different starting materials require different receiving and processing plans. |
| Collection details | Anticoagulant, tube type, collection time, and any known handling deviation. | Collection chemistry and elapsed time can affect recovery, viability, and downstream responses. |
| Geographic and transport plan | Collection location, anticipated transport conditions, and receiving location. | A feasible processing window must be agreed before dispatch; no universal shipping duration is assumed. |
| Target population and use | PBMCs or a specific subset, planned assays, requested number of conditions, and any purity constraints. | The downstream use determines selection, QC, and cell allocation. |
| Sample provenance and permitted use | Relevant research-use documentation and restrictions on processing, analysis, or transfer. | The agreed project must be compatible with the available material and permitted activities. |
For existing cryopreserved PBMCs, include the freezing date if known, storage history, estimated cell content, and any available post-thaw data. A fresh-sample isolation project and a frozen-cell recovery project are different workflows and should not share an assumed acceptance rule.
Selecting Cells Without Losing the Research Question
Subset enrichment can improve the suitability of a preparation for a specific assay, but the method may also change which cells remain in the system. Positive or negative selection is reviewed in relation to target markers, desired cell composition, and downstream stimulation. A purified T cell preparation, for example, may not contain the antigen-presenting compartment needed for a protein-antigen response experiment.
Live-cell preparation and fixed intracellular phenotyping are also separate activities. If the experiment requires viable regulatory T cells, a suitable live enrichment approach and a separate characterization plan are needed. Intracellular marker staining cannot simply be substituted for a live isolation workflow.
From Sample Review to Documented Cell Handover
Review sample type, collection site, anticoagulant, transport plan, and intended assay. Confirm acceptance before collection or shipment.
Document receipt, relevant handling conditions, and the agreed separation or enrichment method. Record deviations that may affect interpretation.
Assess cell count and viability, together with identity, purity, or contamination checks specified for the project.
Prepare the cell quantities and records needed for the next step. Coordinate timing with the downstream team and identify any constraints or failed acceptance criteria.
Quality Measures That Support Useful Cells
A useful preparation needs more than a high percentage viability value. The measurement should identify when viability was assessed, the method used, the recovered cell count, and any required subset purity. If thawing is included, post-thaw recovery and the relevant assay-readiness checks should be specified separately from pre-freeze values.
Expected yield varies with starting material and donor condition. We do not promise a fixed cell yield, universal purity, or a standard processing interval for every sample. Where functional readiness is important, an optional assay-specific check must be agreed rather than inferred from appearance or viability alone.
Connect Preparation with Functional Research
Prepared cells can be allocated to a separately scoped antigen-specific T cell response study, cytokine release assay, or another qualified immune-function experiment. The allocation plan should reserve enough material for controls and QC before all cells are committed to test conditions.
For DC-based research, discuss the downstream differentiation or presentation requirements before selecting a monocyte or PBMC preparation. See DC maturation and antigen presentation testing. This preparation service does not imply clinical-grade cell manufacturing, donor recruitment, or sale of therapeutic cell products.
Preparation Records and Deliverables
| Output | Content to define in the proposal |
|---|---|
| Sample processing record | Sample identifier, receipt and processing information, material type, and relevant handling deviations. |
| Cell recovery data | Recovered count and viability, with the measurement method and assessment time. |
| Identity or purity results | The agreed marker panel or relevant QC finding, reported for the selected population. |
| Handover record | Allocated cell quantities, agreed next-step conditions, and any limitations affecting downstream use. Storage or shipment records are included only if those activities are in scope. |
Frequently Asked Questions
Can blood be shipped without a confirmed processing plan?
Please obtain acceptance and shipping instructions first. The suitable tube, temperature, receiving window, and transport route depend on the material and downstream assay.
Can cryopreserved PBMCs replace fresh cells in every assay?
No. Suitability depends on the population, endpoint, freezing history, and recovery performance. Matching preparation histories is particularly important when comparing experimental groups.
Can I purchase only the preparation step?
Standalone preparation can be discussed during feasibility review. Sample receiving geography, processing capacity, and the intended handover route must be confirmed before a project is accepted.
Is this a clinical cell-processing service?
The proposed service is for research. It does not supply patient treatment, clinical diagnostic interpretation, or an assumed GMP cell-manufacturing workflow.
Research Context
A 2024 paired-sample study compared immunophenotyping across whole blood, fresh PBMCs, and cryopreserved PBMCs. A 2025 study examined processing-related phenotypic and functional changes with particular attention to Tregs. Together, they support documenting the preparation route and validating its suitability for the intended endpoint, rather than treating all PBMC preparations as interchangeable.
References
1. Flow Cytometric Immunophenotyping: Minimal Differences in Fresh and Cryopreserved Peripheral Blood Mononuclear Cells versus Whole Blood. Biomedicines. 2024;12:2319. doi:10.3390/biomedicines12102319.
2. Habibi K, Ågren N, Okada K, et al. Cell Transplantation. 2025;34:09636897251382315. doi:10.1177/09636897251382315.
Review Your Sample Processing Needs
Provide the sample source and collection location, anticoagulant, expected collection-to-processing interval, target cell population, and downstream assay. We will confirm receiving conditions and a feasible preparation plan.